scispace - formally typeset
E

Elisabeth Stockert

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  126
Citations -  17287

Elisabeth Stockert is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Antigen & Antibody. The author has an hindex of 56, co-authored 126 publications receiving 16900 citations. Previous affiliations of Elisabeth Stockert include Cornell University & Ludwig Institute for Cancer Research.

Papers
More filters
Journal ArticleDOI

Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

TL;DR: It is demonstrated that endogenously produced interferon gamma (IFN-gamma) forms the basis of a tumor surveillance system that controls development of both chemically induced and spontaneously arising tumors in mice and is evidenced by the finding that certain types of human tumors become selectively unresponsive to IFN-Gamma.
Journal ArticleDOI

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

TL;DR: R reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma, which indicates that it belongs to an expanding family of immunogenic testicular antigens.
Journal ArticleDOI

A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens

TL;DR: To establish a screening system for the humoral response to autoimmunogenic tumor antigens, an enzyme-linked immunosorbent assay (ELISA) was developed using recombinant NY-ESO-1, MAGE-3, SSX2, Melan-A, and tyrosinase proteins.
Journal ArticleDOI

Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

TL;DR: It is shown that antigen-specific humoral and cellular immune responses against human tumor antigens may occur simultaneously in a single patient and a general strategy is provided for identifying the CTL-recognizing peptides of tumor antIGens initially defined by autologous antibody.